Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin

Ridruejo, Ezequiel; Solano, Angela; Marciano, Sebastián; Galdame, Omar; Adrover, Raúl; Cocozzella, Daniel; Delettieres, Dreanina; Martínez, Alfredo P.; Gadano, Adrián; Mandó, Oscar G.; Silva, Marcelo O.

doi:10.1016/s1665-2681(19)31512-1

Cited by 22 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study we found a prevalence of 22%, closely related to the 24% prevalence previously reported in 84 Mexican patients by Mart ınez-G omez (12). If we look at other studies performed in Latin America, we find 20% prevalence for CC homozygosity in IL-28B rs12979860 in 99 Chilean patients (10) and 18% prevalence (in 102 patients) in a study from Argentina (11). In contrast, in Moroccan and Egyptian populations, a frequency of 67e68% for rs12979860-C allele was reported, significantly higher than the one observed in sub-Saharan African populations (23e55%) (7,18,19).…”

Section: Discussionmentioning

confidence: 73%

A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection

Sixtos-Alonso

Avalos-Martinez

Sandoval-Salas

et al. 2015

Archives of Medical Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 73%

A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection

Sixtos-Alonso

Avalos-Martinez

Sandoval-Salas

et al. 2015

Archives of Medical Research

View full text Add to dashboard Cite

“…Differences in the SVR rates were large and clinically meaningful with a ~2‐fold increase in SVR (70–80% vs 40%) observed in patients carrying the favorable IL28B rs12979860 CC genotype. The association of the IL28B genotype with SVR was confirmed by independent studies in various populations from Asia, Europe, and Latin America . The IL28B wild‐type genotype also indicates an increased likelihood of achieving SVR among a pediatric population (rs12979860 CC p=0.01; rs8099917 TT p=0.07; combined p=0.01) …”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 68%

“…However, rs12979860 was considered a better biomarker for African‐Americans due to the stronger association with SVR compared with rs8099917 . Similarly, stronger associations have been reported with rs12979860 than with rs8099917 in studies that investigated both SNPs . The current consensus is that the rs12979860 genotype is the one most likely to predict treatment response if a single SNP has to be selected for diagnostic purposes .…”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

“…The association of the IL28B genotype with SVR was confirmed by independent studies in various populations from Asia, Europe, and Latin America. [21][22][23][24][25][26][27][28][29] The IL28B wild-type genotype also indicates an increased likelihood of achieving SVR among a pediatric population (rs12979860 CC p=0.01; rs8099917 TT p=0.07; combined p=0.01). 30 Although the wild-type IL28B genotype is a strong baseline predictor of SVR, the genotype alone does not completely differentiate responders and nonresponders.…”

Section: Response To Pegifn/rbv Therapy and Il28bmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

Kawaguchi‐Suzuki

Frye

2013

Pharmacotherapy

View full text Add to dashboard Cite

Hepatitis C virus (HCV) chronically infects 170 million people worldwide. Until recently, combination therapy with peginterferon‐α (pegIFN) and ribavirin (RBV) has been the standard of care. However, for many patients, especially those infected with the most common HCV genotype 1 (HCV‐1), this treatment has resulted in unsatisfactory treatment response rates. Many clinical factors, including pharmacogenetics, influence the treatment response rate. Genetic variation in the interleukin 28B (IL28B) gene is the major determinant of treatment response, a finding that has been replicated in multiple independent cohorts. This review focuses on the association between pharmacogenetics and conventional pegIFN/RBV therapy in patients infected with HCV non–genotype 1; patients reinfected with HCV after liver transplantation; and patients coinfected with HCV and human immunodeficiency virus. We also review the pharmacogenetic data for boceprevir and telaprevir triple therapy in patients with HCV‐1 infection, as well as viral genomic polymorphisms and genetic variants that may protect against anemia. Pharmacogenetic information offers a personalized medicine approach to help clinicians and patients make better informed decisions to maximize response and minimize toxicity for the treatment of chronic HCV infection.

show abstract

“…The relationship between IFNL3 (previously interleukin [IL]-28B) polymorphism and response to treatment was reviewed recently 48. A retrospective study on 102 Latin American patients treated with PEG-RBV in Argentina found that IFNL3 rs12979860-CC and rs8099917-TT genotypes were associated with SVR rates of 64% and 55%, respectively, marking its use as an important tool for planning therapy 49. Other factors such as age, sex, presence of steatosis, obesity, and diabetes mellitus follow in order of importance.…”

Section: Treatment Of Hcvmentioning

confidence: 99%

Hepatitis C in Argentina: epidemiology and treatment

Gaite

Marciano

Galdame

et al. 2014

HMER

Self Cite

View full text Add to dashboard Cite

Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, where from 1.5% to 2.5% of adults are infected. Most of the infections were acquired 30–50 years ago. It is estimated that more than half of infected individuals are not aware of their infection. Even though the prevalence in blood donors has decreased to 0.45% at present, many high-prevalence populations still exist, where the reported prevalence ranges from 2.2% to 7.1%. Therapy is recommended for patients with fibrosis, in order to prevent disease progression, hepatic decompensation, and hepatocellular carcinoma. Great advances were achieved in the treatment of genotype 1 infection since the development and release of boceprevir and telaprevir. When either of these protease inhibitors is associated with peginterferon plus ribavirin, the sustained virological response (SVR) rate improves from 40%–50% to 67%–75%. For genotype 2 and 3 infection, treatment with peginterferon plus ribavirin is still the standard of care, with SVR rates of 70%–90%. There are significant new antivirals in development, and some of them are close to being released. These drugs will most likely be the future standard of care for all genotypes, and will be incorporated in better-tolerated and highly effective all-oral regimes. The impact that these new therapies might have in health-related economics is unpredictable, especially in developing countries. Each country must carefully evaluate the local situation in order to implement proper screening and treatment programs. Difficult-to-treat patients, such as those with decompensated cirrhosis, patients in hemodialysis, and those with other significant comorbidities, might not be able to receive these new therapeutic approaches and their management will remain challenging.

show abstract

Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin

Cited by 22 publications

References 35 publications

A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection

A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection

The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

Hepatitis C in Argentina: epidemiology and treatment

Contact Info

Product

Resources

About